New study identifies potential target for treating diabetic cardiomyopathy

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders.

Up and down the ladder: The latest comings and goings

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s

June 28, 2024

CytomX, Amgen pass on T cell engager; Molecular Partners ends work with Novartis

Plus, news about Atea Pharmaceuticals: CytomX, Amgen stop work on T cell engager: The partners decided to end development of an … Sign up to

March 8, 2025

Study identifies a new biomarker for Alzheimer’s disease in asymptomatic stages

A recent study led by the Molecular and Cellular Neurobiotechnology group at the Institute for Bioengineering of Catalonia (IBEC) and the University of Barcelona has

May 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.